Masimo [MASI] vs Abbott Laboratories [ABT] Detailed Stock Comparison
Masimo
NASDAQ
Loading...
Abbott Laboratories
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Masimo wins in 5 metrics, Abbott Laboratories wins in 14 metrics, with 0 ties. Abbott Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Masimo | Abbott Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 129.16 | 16.44 | Abbott Laboratories |
| Price-to-Book Ratio | 7.82 | 4.51 | Abbott Laboratories |
| Debt-to-Equity Ratio | 61.58 | 26.50 | Abbott Laboratories |
| PEG Ratio | 32.36 | 25.39 | Abbott Laboratories |
| EV/EBITDA | 55.26 | 20.53 | Abbott Laboratories |
| Profit Margin (TTM) | -21.32% | 32.43% | Abbott Laboratories |
| Operating Margin (TTM) | 17.12% | 19.73% | Abbott Laboratories |
| EBITDA Margin (TTM) | 17.12% | 19.73% | Abbott Laboratories |
| Return on Equity | -22.37% | 30.93% | Abbott Laboratories |
| Return on Assets (TTM) | 1.84% | 6.62% | Abbott Laboratories |
| Free Cash Flow (TTM) | $145.30M | $6.35B | Abbott Laboratories |
| Dividend Yield | N/A | 1.28% | N/A |
| 1-Year Return | 24.66% | 18.69% | Masimo |
| Price-to-Sales Ratio (TTM) | 3.79 | 5.29 | Masimo |
| Enterprise Value | $8.50B | $235.08B | Abbott Laboratories |
| EV/Revenue Ratio | 3.95 | 5.45 | Masimo |
| Gross Profit Margin (TTM) | 62.90% | 56.44% | Masimo |
| Revenue per Share (TTM) | $40 | $25 | Masimo |
| Earnings per Share (Diluted) | $-5.08 | $7.97 | Abbott Laboratories |
| Beta (Stock Volatility) | 1.21 | 0.71 | Abbott Laboratories |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Masimo vs Abbott Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Masimo | 1.32% | 6.32% | -3.86% | -0.34% | -14.69% | -8.72% |
| Abbott Laboratories | 1.91% | -1.88% | 0.20% | -1.20% | 1.21% | 16.14% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Masimo | 24.66% | -1.19% | -29.80% | 270.50% | 555.88% | 668.58% |
| Abbott Laboratories | 18.69% | 19.71% | 28.66% | 179.55% | 456.61% | 499.14% |
Performance & Financial Health Analysis: Masimo vs Abbott Laboratories
| Metric | MASI | ABT |
|---|---|---|
| Market Information | ||
| Market Cap | $8.16B | $228.04B |
| Market Cap Category | Mid cap | Mega cap |
| 10 Day Avg. Volume | 1,111,551 | 5,619,133 |
| 90 Day Avg. Volume | 719,827 | 7,036,484 |
| Last Close | $153.87 | $131.75 |
| 52 Week Range | $107.98 - $194.88 | $109.76 - $141.23 |
| % from 52W High | -21.04% | -6.71% |
| All-Time High | $305.21 (Nov 15, 2021) | $142.60 (Dec 27, 2021) |
| % from All-Time High | -49.59% | -7.61% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.08% | 0.07% |
| Quarterly Earnings Growth | 2.21% | 0.37% |
| Financial Health | ||
| Profit Margin (TTM) | -0.21% | 0.32% |
| Operating Margin (TTM) | 0.17% | 0.20% |
| Return on Equity (TTM) | -0.22% | 0.31% |
| Debt to Equity (MRQ) | 61.58 | 26.50 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $19.20 | $29.05 |
| Cash per Share (MRQ) | $2.75 | $4.18 |
| Operating Cash Flow (TTM) | $176.60M | $9.04B |
| Levered Free Cash Flow (TTM) | $92.86M | $5.92B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.28% |
| Last 12-Month Dividend | $0.00 | $1.69 |
Valuation & Enterprise Metrics Analysis: Masimo vs Abbott Laboratories
| Metric | MASI | ABT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 129.16 | 16.44 |
| Forward P/E | 32.36 | 25.39 |
| PEG Ratio | 32.36 | 25.39 |
| Price to Sales (TTM) | 3.79 | 5.29 |
| Price to Book (MRQ) | 7.82 | 4.51 |
| Market Capitalization | ||
| Market Capitalization | $8.16B | $228.04B |
| Enterprise Value | $8.50B | $235.08B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.95 | 5.45 |
| Enterprise to EBITDA | 55.26 | 20.53 |
| Risk & Other Metrics | ||
| Beta | 1.21 | 0.71 |
| Book Value per Share (MRQ) | $19.20 | $29.05 |
Financial Statements Comparison: Masimo vs Abbott Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | MASI | ABT |
|---|---|---|
| Revenue/Sales | $372.00M | $10.36B |
| Cost of Goods Sold | $138.00M | $4.47B |
| Gross Profit | $234.00M | $5.89B |
| Research & Development | $33.90M | $716.00M |
| Operating Income (EBIT) | $80.70M | $1.69B |
| EBITDA | $90.70M | $2.66B |
| Pre-Tax Income | $68.40M | $1.78B |
| Income Tax | $21.20M | $453.00M |
| Net Income (Profit) | $-170.70M | $1.33B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | MASI | ABT |
|---|---|---|
| Cash & Equivalents | $130.80M | $6.53B |
| Total Current Assets | $1.18B | $23.15B |
| Total Current Liabilities | $546.50M | $13.00B |
| Long-Term Debt | $657.70M | $12.74B |
| Total Shareholders Equity | $946.40M | $49.06B |
| Retained Earnings | $1.32B | $47.72B |
| Property, Plant & Equipment | $183.60M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | MASI | ABT |
|---|---|---|
| Operating Cash Flow | $62.60M | $1.42B |
| Capital Expenditures | $17.00M | $-484.00M |
| Free Cash Flow | $27.00M | $933.00M |
| Debt Repayment | $-78.80M | $-1.00B |
| Common Stock Repurchase | N/A | $-280.00M |
Short Interest & Institutional Ownership Analysis
| Metric | MASI | ABT |
|---|---|---|
| Shares Short | 3.27M | 18.33M |
| Short Ratio | 6.08 | 2.44 |
| Short % of Float | 0.09% | 0.01% |
| Average Daily Volume (10 Day) | 1,111,551 | 5,619,133 |
| Average Daily Volume (90 Day) | 719,827 | 7,036,484 |
| Shares Outstanding | 53.60M | 1.73B |
| Float Shares | 45.31M | 1.73B |
| % Held by Insiders | 0.08% | 0.01% |
| % Held by Institutions | 1.02% | 0.81% |
Dividend Analysis & Yield Comparison: Masimo vs Abbott Laboratories
| Metric | MASI | ABT |
|---|---|---|
| Last 12-Month Dividend | $0.00 | $1.69 |
| Last 12-Month Dividend Yield | N/A | 1.28% |
| 3-Year Avg Annual Dividend | $0.00 | $1.92 |
| 3-Year Avg Dividend Yield | N/A | 0.49% |
| 3-Year Total Dividends | $0.00 | $5.77 |
| Ex-Dividend Date | N/A | Jan 15, 2025 |